Home › Funds › ADAR1 Capital Management, LLC › CTMX
ADAR1 Capital Management, LLC position in CTMX
CYTOMX THERAPEUTICS INC. · Health Care
ADAR1 Capital Management, LLC reported holding 3,365,118 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q2 2026 13F filing — a position valued at US$12.6M, representing 0.70% of its reported portfolio and ranking #40 among its reported holdings. ADAR1 Capital Management, LLC has disclosed CTMX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's CTMX position evolved
ADAR1 Capital Management, LLC first disclosed a stake in CTMX in Q1 2024 at 155,000 shares (US$338K). The position peaked in Q1 2026 at 3,410,190 shares, worth US$16.0M. Across 10 filings, ADAR1 Capital Management, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,365,118 shares valued at US$12.6M — a reduction of -45,072 shares quarter over quarter.. Notable position changes include a 269% increase in Q2 2024 (shares fell 3% over the following quarter), a 6451% increase in Q2 2025 (shares rose 41% over the following quarter), a 3310% increase in Q1 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 155.00K | $337.90K | New |
| Q2 2024 | 572.17K | $698.05K | Add |
| Q3 2024 | 903.96K | $1.07M | Add |
| Q4 2024 | 145.04K | $149.39K | Reduce |
| Q1 2025 | 47.04K | $29.91K | Reduce |
| Q2 2025 | 3.08M | $6.99M | Add |
| Q3 2025 | 4.05M | $12.90M | Add |
| Q4 2025 | 100.00K | $426.00K | Reduce |
| Q1 2026 | 3.41M | $16.03M | Add |
| Q2 2026 | 3.37M | $12.62M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTMX and 13F data
CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 45 other funds we track also report a position in CTMX — the largest reported positions include Kynam Capital Management, LP (US$81.4M), PERCEPTIVE ADVISORS LLC (US$39.1M), Venrock Adviser, LLC (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTMX
- Kynam Capital Management, LP 21.70M sh · $81.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.44M sh · $39.15M · Q2 2026
- Venrock Adviser, LLC 4.98M sh · $18.68M · Q2 2026
- Elmind Capital, LP 4.55M sh · $17.06M · Q2 2026
- Nextech Invest Ltd. 4.45M sh · $16.69M · Q2 2026
- Eversept Partners, LP 3.56M sh · $13.34M · Q2 2026
- Seven Fleet Capital Management LP 1.09M sh · $4.07M · Q2 2026
- Ally Bridge Group (NY) LLC 775.00K sh · $2.91M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held CTMX?
ADAR1 Capital Management, LLC has disclosed CTMX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is ADAR1 Capital Management, LLC's current position in CTMX?
As of Q2 2026, ADAR1 Capital Management, LLC holds 3.37M shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $12.62M, representing 0.70% of its reported portfolio and ranking #40.
Has ADAR1 Capital Management, LLC been buying or selling CTMX?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in CTMX. The position peaked in Q1 2026 at 3.41M shares.
Which other funds hold CTMX?
Other major institutional holders of CTMX include Kynam Capital Management, LP, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.